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Abstract
Delphinidin-3-glucoside (Dp-3-g) is one of the predominant bioactive compounds of anthocyanins in many plant foods.
Although several anthocyanin compounds have been reported to be protective against cardiovascular diseases (CVDs), the
direct effect of anthocyanins on platelets, the key players in atherothrombosis, has not been studied. The roles of Dp-3-g in
platelet function are completely unknown. The present study investigated the effects of Dp-3-g on platelet activation and
several thrombosis models in vitro and in vivo. We found that Dp-3-g significantly inhibited human and murine platelet
aggregation in both platelet-rich plasma and purified platelets. It also markedly reduced thrombus growth in human and
murine blood in perfusion chambers at both low and high shear rates. Using intravital microscopy, we observed that Dp-3-g
decreased platelet deposition, destabilized thrombi, and prolonged the time required for vessel occlusion. Dp-3-g also
significantly inhibited thrombus growth in a carotid artery thrombosis model. To elucidate the mechanisms, we examined
platelet activation markers via flow cytometry and found that Dp-3-g significantly inhibited the expression of P-selectin,
CD63, CD40L, which reflect platelet a- and d-granule release, and cytosol protein secretion, respectively. We further
demonstrated that Dp-3-g downregulated the expression of active integrin aIIbb3 on platelets, and attenuated fibrinogen
binding to platelets following agonist treatment, without interfering with the direct interaction between fibrinogen and
integrin aIIbb3. We found that Dp-3-g reduced phosphorylation of adenosine monophosphate-activated protein kinase,
which may contribute to the observed inhibitory effects on platelet activation. Thus, Dp-3-g significantly inhibits platelet
activation and attenuates thrombus growth at both arterial and venous shear stresses, which likely contributes to its
protective roles against thrombosis and CVDs.
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Introduction
Platelets are small anucleate cells in the blood that can sense
environmental changes, including the alteration of nutrition
products of food in the blood circulation [1–4]. Platelets are
versatile cells and play important roles in hemostasis/thrombosis,
inflammation, and atherosclerosis [5,6]. Platelet adhesion and
subsequent aggregation at the site of vascular injury are key events
required for hemostasis. However, excessive platelet accumulation
and thrombus formation may result in thrombotic diseases such as
myocardial infarction or stroke, the two leading causes of
morbidity and mortality worldwide. Many cardiovascular diseases
(CVDs), including the initiation of atherosclerosis, are linked to
platelet hyperactivity, the abnormal, excessive activation of
platelets, which is considered an independent risk factor for CVDs
[7,8].
At the site of vascular injury, particularly at high shear stress,
such as rupture of atherosclerotic lesions in coronary arteries, the
binding of the platelet glycoprotein (GP)Ib complex to von
Willebrand factor (VWF) on the injured vessel wall initiates
platelet tethering and subsequent adhesion. Platelet aggregation is
then mediated by interaction between platelet aIIbb3 integrin and
fibrinogen (Fg), although Fg-independent platelet aggregation, as
we demonstrated, can also occur [9–11]. Platelet activation,
induced by platelet agonists such as adenosine diphosphate (ADP),
collagen, and thrombin at the site of injury, is an important
process for platelet adhesion and aggregation. Following activa-
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(CD62P), CD63 and CD40L, may translocate to the cell surface.
Platelet activation also results in the conversion of aIIbb3 integrin
to an active conformation, allowing it to bind ligands including Fg
and other proteins [9–11]. The translocation and conformational
changes of these proteins after platelet activation facilitates the
interaction of platelets with their environment (e.g. extracellular
matrix proteins on the vessel wall and aIIbb3 integrin ligands in
the blood during platelet adhesion and aggregation), which are
important processes for hemostasis and thrombosis, as well as for
inflammation and atherosclerosis. Therefore, downregulating
platelet activation may be a feasible approach for preventing
and treating CVDs resulting from platelet hyperactivation.
Mounting epidemiological information suggests that dietary
intake of plant foods rich in phytochemicals is negatively
associated with CVDs [12]. The polyphenols are a well-studied
group of phytochemicals, among which the anthocyanins have
been shown to impart significant beneficial properties [13,14].
Anthocyanins are abundant in various fruits and vegetables and
their related products, including grapes, berries, red cabbage and
red wine. Our previous studies, in addition to those of other
research groups, have demonstrated that intake of anthocyanin-
rich beverages or pure anthocyanins inhibits atherosclerosis
through anti-oxidative and anti-inflammatory properties [15,16],
as well as by improving lipid profiles and endothelium-dependent
vasodilatation [15,17–19]. Furthermore, some studies have shown
that dietary supplementation with anthocyanins imparts anti-
thrombotic effects by modulating platelet aggregation and function
in human whole blood and platelet-rich plasma (PRP) [20]. Our
recent studies have also shown that anthocyanin extract from
black rice facilitates the maintenance of optimal platelet function
in dyslipidemic rats consuming high fat diets [3]. In contrast, some
studies suggested that steady consumption of anthocyanin
supplements did not significantly affect platelet aggregation
[21,22]; therefore, the conclusions drawn from human studies
are contradictory and further investigation of the effects of
anthocyanins on platelet function are required.
In addition to differences in methodologies, the seemingly
contradictory results from studies evaluating the effects of
anthocyanins on platelet function may be because the majority
of studies have focused on polyphenolic-rich foods or beverages,
such as grape juice [23] and red wine [24], which contain multiple
compounds and different concentrations or subclasses of antho-
cyanins. Other important factors to consider are that in humans,
the rate of absorption and elimination of, as well as the relative
bioavailability of, anthocyanins present in different foods is
unclear. Therefore, it is important to examine the direct effects
of pure anthocyanins on platelet function in order to elucidate
their mechanisms of action in vitro and in vivo. To date, the anti-
platelet activity of four purified anthocyanins (delphinidin-3-
rutinoside, cyanidin-3-glucoside, cyanidin-3-rutinoside, and mal-
vidin-3-glucoside) have been assayed in human whole blood and
PRP [20]. However, to the best of our knowledge, the direct role
of purified anthocyanins on platelet function and their effects on
thrombus formation under flow conditions has not been studied.
Delphinidin-3-glucoside (Dp-3-g), one of the predominantly
bioactive compounds of anthocyanin preparations, is a natural
colorant found in bilberries and other fruits and flowers [25].
Some studies have shown that it has beneficial effects on human
low-density lipoprotein cholesterol oxidation [26]; however,
differing from other anthocyanin compounds, its roles in platelet
function (including in PRP) and thrombosis are completely
unknown. In the present study, we determined whether Dp-3-g
could alter platelet aggregation in both PRP and purified gel-
filtered platelets, as well as in several thrombosis models in vitro and
in vivo. We found that Dp-3-g significantly inhibits platelet
aggregation, and attenuates thrombus growth under both arterial
and venous shear stresses. We demonstrated that Dp-3-g inhibited
platelet activation and attenuated platelet adenosine monopho-
sphate-activated protein kinase (AMPK) phosphorylation, which
may explain its protective role against thrombosis and other
CVDs.
Materials and Methods
Ethics Statement
For research involving human participants, written informed
consent was obtained in accordance with the Declaration of
Helsinki and studies were approved by the St. Michael’s Hospital
Research Ethics Board. All animal procedures were approved by
the Animal Care Committee at St. Michael’s Hospital (protocol
numbers 213 and 181). Mice were housed in the research vivarium
at St. Michael’s Hospital.
Reagents
Dp-3-g was purchased from Polyphenol AS (Norway). Throm-
bin receptor activating peptide (TRAP; AYPGKF-NH2) was
purchased from Peptides International (Louisville, MO, USA).
Thrombin and ADP were purchased from Sigma-Aldrich
(Oakville, ON, Canada). Type-I collagen fibrils (equine collagen
Horm) was purchased from Nycomed (Roskilde, Denmark).
DiOC6 dye was purchased from Invitrogen (Burlington, ON,
Canada). PE-conjugated mouse anti-human PAC-1 antibody,
FITC-conjugated mouse anti-human CD63 antibody, FITC-
conjugated mouse anti-human CD40L antibody, FITC-conjugat-
ed mouse anti-human CD62P antibody, PE-conjugated mouse
anti-mouse CD62P antibody, FITC-conjugated mouse IgG1k
Isotype control, PE-conjugated anti-mouse IgG antibody, FITC-
conjugated mouse anti-human IgG1k Isotype control and PE-
conjugated anti-human IgG1k Isotype control were purchased
from BD Biosciences (Mississauga, ON, Canada). PE-conjugated
goat anti-mouse JON/A antibody was purchased from Emfret
Analytics (Eibelstadt, Germany). Rabbit antibodies against phos-
phorylated AMPK (pAMPK, Thr172) and AMPK were pur-
chased from Cell Signaling Technology (Danvers, MA, USA). Fg
from human plasma, Alexa Fluor 488 conjugate and Calcein AM
was purchased from Invitrogen (Burlington, ON, Canada).
Mice
C57BL/6J mice were purchased from Charles River Labora-
tories International (Wilmington, MA).
Murine platelet and plasma preparation
Mice (6–8 weeks old) were anesthetized and bled from the retro-
orbital plexus with the use of heparin-coated glass capillary tubes.
Blood was collected into tubes containing either 3% ACD (1/9
vol/vol) or 25 U/mL heparin. PRP was obtained by centrifuga-
tion at 300 g for 7 min. Platelet-poor plasma (PPP) was prepared
by centrifugation at 1500 g for 20 min. The PPP was further
centrifuged at 10,000 g for 5 min to remove any remaining cells.
Gel-filtered platelets were prepared as previously described
[27,28]. Briefly, platelets were isolated from citrated PRP using
a Sepharose 2B column in PIPES buffer (5 mM PIPES, 1.37 mM
NaCl, 4 mM KCl, 0.1% (wt/vol) glucose, pH 7.0).
Human blood preparation
Blood was obtained from healthy human subjects who had not
taken any anti-platelet medication in the prior two week period.
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and was allowed to rest at 37uC for 10 min prior to preparation of
PRP. Whole anticoagulated blood was spun at 300 g for 7 min.
The PRP was transferred to a fresh tube and stored at 37uC until
use. Gel-filtered platelets were prepared using the same method as
for preparation of murine gel-filtered platelets.
Platelet Aggregation
Aggregation of PRP and gel-filtered platelets were performed at
37uC with a sample stir speed of 1000 rpm using a computerized
aggregometer (Chrono-Log Corp, Havertown, PA) as we pre-
viously described [10,11]. PRP and gel-filtered platelets were pre-
incubated with the indicated doses of anthocyanin or control
buffer for 40 min at 37uC. For PRP, the baseline was adjusted
with PPP, and for gel-filtered platelets, equal amounts of platelets
were mixed with PIPES (final concentration ,2.5610
8 platelets/
mL). A total of 250 mL of each sample was added to an
aggregation cuvette and incubated for 2 min. Aggregation was
induced by 5 mM ADP, 100 mM TRAP, 0.1 U/mL thrombin or
2 mg/mL collagen in the presence of 1 mM Ca
2+. Aggregation
was recorded for 8 min, and data were expressed as a percentage
of maximum aggregation of the control without pre-incubation
with Dp-3-g.
Perfusion flow assays
The ex vivo perfusion chamber thrombosis model was performed
at low (600 s
21) and high (1800 s
21) shear rates, as we previously
described [10]. Briefly, rectangular (0.161 mm) glass capillary
microslides were coated with 100 mg/mL type-I collagen fibrils
overnight at 4uC. Where indicated, whole blood was pre-
incubated with different levels of Dp-3-g or control buffer alone
for 40 min at 37uC prior to perfusion, followed by washout with
phosphate buffered saline (PBS). Platelet adhesion, aggregation,
and thrombus formation were recorded in real-time over the
course of perfusion under bright field with a Zeiss Axiovert 135
inverted microscope and computer (IBM IntelliStation Z Pro)
using the Slidebook program (Intelligent Imaging Innovations).
Surface coverage and thrombus size were calculated from the light
microscope images using ImageJ software.
Intravital microscopy thrombosis models
The process of thrombus formation in arterioles was monitored
in 3–4 week old mice, as we previously described [9–11,27,29].
Briefly, blood was collected into ACD (1:10) from the experimen-
tal mice. PRP was prepared by centrifugation. Platelets were
separated from plasma by gel-filtration, labeled with 1 mg/mL of
Calcein AM at room temperature for 20 min, and then injected
into the experimental mouse (1.25610
6 platelets/g) via the tail
vein. Mice were then anesthetized and the mesentery was
externalized. In each mouse, a single mesenteric arteriole of
100–120 mm diameter was chosen and injury was induced by
topical application of 30 mL of 250 mM FeCl3. Control buffer or
Dp-3-g was injected via the tail vein 40 min before FeCl3
application. Images of thrombus formation and dissolution were
visualized with a fluorescence microscope (Zeiss Axiovert 135;
Zeiss Oberkochen) and compared between groups based on the
time to complete vessel occlusion, as previously described [27,29].
Carotid artery thrombosis model
C57BL/6 mice (6-weeks old) were injected with 50 mM Dp-3-g
or control buffer via the tail vein. Following anesthetization, the
right carotid artery was dissected and held with a miniature
Doppler flow probe (TS420 transit-time perivascular flowmeter,
Transonic Systems Inc.). Carotid artery injury was induced with
a strip of Whatman filter paper saturated with 10% ferric chloride
[30]. The blood flow was monitored until complete vessel
occlusion was observed.
Bleeding time assay
C57BL/6 mice (6–8 weeks old) were injected with either control
buffer or Dp-3-g intravenously via the tail vein 40 min before the
bleeding time was assessed. Mice were anesthetized with 2.5%
tribromoethanol (0.015 mL/g) and maintained at 37uCo n
a heating pad during the experiment. The tip of the tail (5 mm)
was cut off with a sharp scalpel, and the tail was immediately
placed into warm saline at 37uC. The bleeding time was the period
from the moment blood began emerging from the cut until the
moment bleeding ceased.
Detection of P-selectin expression on human and mouse
platelets
Human and mouse PRP and gel-filtered platelets were in-
cubated with different concentrations of Dp-3-g or control buffer
for 40 min at 37uC. Aliquots of sample (100 mL) were transferred
to tubes containing saturating concentrations of the following
fluorescently-labeled monoclonal antibodies: PE-conjugated anti-
human CD62P antibody, FITC-conjugated anti-mouse CD62P
antibody, PE/FITC-conjugated anti-mouse/human IgG1k (iso-
tope controls), and incubated for 15 min at room temperature.
PRP or gel-filtered platelets were activated with either 200 mM
ADP, 250 mM TRAP, 10 mg/mL collagen or 1 U/mL thombin,
for 5 min at room temperature. PBS (0.5 mL) was added to each
sample immediately before acquisition. All samples were analyzed
via a calibrated FACSCalibur flow cytometer (BD Biosciences).
Ten thousand events per sample were acquired; light scatter and
fluorescence channels were set at a logarithmic gain, the platelet
population was analyzed for mean fluorescence intensity (MFI).
For each experiment, all samples for comparison were acquired at
the same settings.
Detection of CD63 and CD40L expression on human
platelets
Human gel-filtered platelets were incubated with different
concentrations of Dp-3-g or control buffer for 40 min at 37uC.
To label CD63 and CD40L, platelets were incubated with FITC-
conjugated mouse anti-human CD63 or anti-human CD40L for
15 min at room temperature. Gel-filtered platelets were activated
with 1 U/mL thrombin, 250 mM TRAP or 10 mg/mL collagen in
the presence of 1 mM Ca
2+ for 5 min. The platelets were fixed
with 1% paraformaldehyde before being analyzed via flow
cytometry.
Detection of activated integrin aIIbb3 expression on
human and mouse platelets
The expression of activated integrin aIIbb3 on human and
murine platelets, measured by PAC-1 and JON/A antibody,
respectively, were tested as we previously described [31]. PRP or
gel-filtered platelets were incubated in polystyrene tubes for
40 min at 37uC with different concentrations of Dp-3-g or control
buffer. Aliquots of sample (100 mL) were transferred to tubes
containing saturating concentrations of the following fluorescently-
labeled monoclonal antibodies: FITC-conjugated anti-human
PAC-1 antibody, FITC-conjugated anti-human IgG1k (isotype
control), PE-conjugated anti-mouse JON/A antibody or PE-
conjugated mouse IgG1k (isotype control), and incubated for
15 min at room temperature. Samples in the presence or absence
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PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e37323of the agonists 200 mM ADP, 250 mM TRAP, or 10 mg/mL
collagen were incubated for 5 min at room temperature. The
samples were then fixed in filtered 1% paraformaldehde (pH 7.2)
and stored in the dark at 4uC. All samples were analyzed via flow
cytometry.
Detection of platelet-bound fibrinogen on human and
mouse platelets
Resting gel-filtered platelets were incubated with different
concentrations of Dp-3-g or control buffer for 40 min at 37uC,
and were then incubated with FITC-conjugated Fg for 15 min at
room temperature. Platelet activation was induced by 200 mM
ADP, 250 mM TRAP, 10 mg/mL collagen or 1 U/mL thrombin
for 5 min at room temperature. The samples were then fixed in
filtered 1% paraformaldehyde (pH 7.2) and stored in the dark at
4uC. All samples were analyzed via flow cytometry.
Detection of threonine phosphorylation of AMPK in
human and mouse platelets
Gel-filtered platelets were pre-incubated with the indicated
doses of Dp-3-g or control buffer for 40 min at 37uC. Platelets
were activated with 25 mg/mL collagen for 90 s at room
temperature. Platelets were solubilized in Triton X-100 lysis
buffer, and 20 mg of soluble proteins were separated by sodium
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE).
Western blotting was performed as previously described [32].
Membranes were blocked with 5% (w/v) skim milk powder in
Tris-buffered saline-Tween (TBS-T; 20 mM Tris, 137 mM NaCl,
0.1% (v/v) Tween 20, pH 7.6). Primary antibody that specifically
recognizes phosphorylated AMPK (pAMPK) residue Thr172 and
horseradish peroxide (HRP)-conjugated secondary antibody (anti-
rabbit IgG-HRP) were diluted 1:1000 and 1:2000, respectively, in
TBS-T containing 5% (w/v) bovine serum albumin (BSA). Blots
were developed with ECL detection reagents (Thermo Scientific)
according to the manufacturer’s instructions. Following detection,
the same membranes were stripped with stripping buffer and re-
blotted with a primary antibody that recognizes total AMPK.
Figure 1. Effects of Dp-3-g on human platelet aggregation. Human PRP and gel-filtered platelets were pre-incubated with control buffer
(black), 0.5 mM Dp-3-g (blue), 5 mM (green) or 50 mM Dp-3-g (red) for 40 min at 37uC. Platelet aggregation with human PRP or gel-filtered platelets
was performed at 37uC with a stir speed of 1000 rpm using an aggregometer. A) Human PRP. B) Human gel-filtered platelets. Values are mean 6 SD,
n=3 per group. * P,0.05, ** P,0.01 and *** P,0.001, as compared to control buffer.
doi:10.1371/journal.pone.0037323.g001
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Data from each treatment or control group were analyzed by
one-way ANOVA coupled with the Student-Newman-Keuls
multiple comparison test using the SPSS 16.0 statistical package.
Differences were considered significant if P,0.05.
Results
Dp-3-g inhibited platelet aggregation following
stimulation of platelets with various agonists
The effects of Dp-3-g on platelet function have not been
previously explored. We found that Dp-3-g significantly inhibited
platelet aggregation following stimulation with ADP, collagen or
TRAP in both human PRP (Figure 1A) and mouse PRP (Figure
S1A) in a dose-dependent manner. Dp-3-g markedly inhibited
ADP-induced human platelet aggregation at doses as low as
0.5 mM, although significant inhibition of platelet aggregation
induced by the strong agonists collagen and TRAP was observed
at higher doses. To distinguish whether this inhibition was directly
due to the effect of Dp-3-g on platelets but not due to indirect
effects following possible interactions with other blood compo-
nents, human and mouse platelets were isolated via gel-filtration.
Dp-3-g significantly inhibited aggregation of purified human
platelets induced by collagen, thrombin or TRAP (P,0.01) in
a dose-dependent manner (Figure 1B). Dp-3-g also significantly
inhibited aggregation of purified mouse platelets induced by these
agonists. Significant inhibition of collagen- and TRAP-induced
platelet aggregation was observed at Dp-3-g doses as low as
0.5 mM( Figure S1B).
Dp-3-g inhibited human and mouse thrombus formation
in ex vivo flow chambers
To evaluate the effects of Dp-3-g on platelet thrombus
formation under flow conditions, we performed perfusion experi-
ments using glass coverslips coated with type I collagen fibrils.
Consistent with the data from in vitro platelet aggregation, we
observed that Dp-3-g significantly inhibited human thrombus
formation at both low (600 s
21)( Figure 2A) and high shear rates
(1800 s
21)( Figure 2B) in a dose-dependent manner. Significant
inhibition was observed at doses as low as 0.5 mM under both the
low (P,0.01) and high shear rates (P,0.05). Marked inhibition of
mouse thrombus growth was also observed following the addition
of different concentrations of Dp-3-g to heparin-anticoagulated
murine blood (Figure S2A–S2B).
Dp-3-g inhibited murine thrombus growth in vivo
To test the effects of anthocyanin on thrombus formation in vivo,
we first used FeCl3-induced mesenteric arteriole injury in an
intravital microscopy thrombosis model. We found that Dp-3-g
decreased platelet deposition and prolonged the time required for
thrombus formation and vessel occlusion (Figure 3A). Compared
to the control group, thrombus growth was reduced at a dose of
0.5 mM and vessel occlusion was significantly delayed in the 5 mM
and 50 mM Dp-3-g treatment groups (P,0.01).
We further examined this effect on large vessels using a carotid
artery thrombosis model [30]. We found that vessel occlusion time
was significantly delayed in the 50 mM Dp-3-g treatment group
(P,0.05) compared to the control group (Figure 3B).
Dp-3-g did not significantly affect bleeding time in mice
To investigate the effect of Dp-3-g on normal hemostasis,
bleeding times were measured 40 minutes after Dp-3-g or control
buffer was injected intravenously via the mouse tail vein. No
significant difference in tail-bleeding times was observed in wild-
type mice treated with different doses of Dp-3-g versus control
buffer (Figure 4). This is consistent with an earlier observation
that thrombosis is more sensitive than hemostasis in response to
platelet inhibitors [33].
Dp-3-g inhibited P-selectin expression on human and
murine platelets after agonist stimulation
To investigate the effects of anthocyanin Dp-3-g on platelet
activation, P-selectin expression on human and murine platelets
was examined via flow cytometry. We found that Dp-3-g inhibited
platelet P-selectin expression after stimulation with high doses of
ADP, collagen or TRAP (Figure 5A). Significant inhibition was
observed with 50 mM Dp-3-g (P,0.05) for human PRP. The
inhibitory effect was also observed at 5 mM and 50 mM Dp-3-g
(P,0.05) for mouse PRP (Figure S3A). Thus, Dp-3-g inhibited
platelet a-granule release in PRP.
It is currently unknown whether the anthocyanin Dp-3-g can
directly affect platelet activation or act on other molecules in blood
plasma that indirectly affect the platelet activation process. We
therefore examined P-selectin expression on purified gel-filtered
platelets. Significantly less P-selectin expression was observed
following stimulation by collagen, thrombin or TRAP at 5 mM
and 50 mM Dp-3-g (P,0.05). The MFI decreased approximately
50% and 70% compared with controls (Figure 5B). The weak
agonist ADP was not used for these experiments since it is usually
unable to induce granule release in gel-filtered platelets. Consistent
with human gel-filtered platelets, a significant decrease in P-
selectin on mouse purified platelets was also observed (Figure
S3B). These data clearly demonstrate that Dp-3-g can directly
inhibit platelet P-selectin expression in a dose-dependent manner.
Dp-3-g significantly inhibited CD63 and CD40L
expression on human platelets
Recent research has suggested that platelets can sense different
signals during activation and selectively release their granules
[34,35]. We therefore examined the d-granule secretion marker,
CD63, and a platelet cytoplasmic inflammatory factor, CD40L.
Since expression of these markers is relatively low, we used strong
agonists to induce platelet activation in gel-filtered platelets. Dp-3-
g significantly decreased both CD63 and CD40L expression on
human gel-filtered platelets following stimulation with various
agonists (P,0.05) (Figure 5C–5D), and was able to inhibit CD63
expression at concentrations as low as 0.5 mM. Thus, in addition
to its inhibitory effect on platelet a-granules, Dp-3-g can also
inhibit platelet d-granule release, as well as cytosol protein
secretion, in a dose-dependent manner.
Dp-3-g significantly inhibited expression of active
integrin aIIbb3 on human and mouse platelets
Integrin aIIbb3, an abundant platelet membrane protein, is
required for platelet aggregation [11,36]. During platelet activa-
tion, aIIbb3 switches from an inactive to an active conformation,
which reveals the epitope for the monoclonal antibodies, PAC-1
and JON/A for human and murine aIIbb3, respectively. We
found that Dp-3-g significantly inhibited platelet PAC-1 binding in
both human PRP and gel-filtered platelets following platelet
stimulation with ADP, collagen, TRAP or thrombin (P,0.05)
(Figure 6A–6B). It also inhibited murine platelet JON/A binding
in mouse PRP and gel-filtered platelets (P,0.05) (Figure S3C–
S3D).
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human and mouse platelets
Fg is a major ligand of integrin aIIbb3 and the engagement of
Fg with activated aIIbb3 plays a key role in platelet aggregation
and thrombus formation. We found that Dp-3-g significantly
inhibited Fg binding to both human PRP and gel-filtered platelets
after stimulation by ADP, collagen, TRAP or thrombin (P,0.05)
(Figure 6C–6D). Similar effects were also observed in murine
PRP and gel-filtered platelets (P,0.05) (Figure S3E–S3F). This
inhibitory effect is unlikely due to a direct interaction between Dp-
3-g and aIIbb3 (data not shown) as no competition was observed
between Fg and purified aIIbb3 integrin-coated wells via ELISA
or aIIbb3 integrin-coated latex beads via flow cytometry.
Dp-3-g significantly inhibited AMPK phosphorylation in
human and mouse platelets
AMPK is a key sensor of cellular energy status [37], and platelet
activation is an energy-consuming process. Our group, as well as
other laboratories, recently demonstrated that anthocyanins affect
AMPK phosphorylation in cells of several distinctive tissues
[32,38,39], but their effect on platelet AMPK has not been
explored. To determine whether Dp-3-g affects the phosphoryla-
tion of AMPK, which has recently been implicated in platelet
signalling [40], platelet pAMPK levels were examined following
collagen activation. Compared to the control group, pAMPK
levels in human platelets were reduced in a dose-dependent
manner and significant reduction was observed in the presence of
5 and 50 mM Dp-3-g (P,0.05 and P,0.01, respectively)
(Figure 7A). A similar dose-dependent reduction in pAMPK
was also observed in collagen-activated murine platelets (P,0.05)
(Figure 7B).
Discussion
The present study demonstrates that Dp-3-g, one of the
predominantly bioactive compounds of anthocyanins, inhibits
platelet activation and aggregation, as well as attenuates throm-
bosis in vitro and in vivo. To the best of our knowledge, this is the
first study that clearly demonstrates that an anthocyanin can
directly inhibit platelet function, in addition to its potential effects
on inflammation [15,16] and lipid metabolism [18] that may
indirectly alter platelet activities. Compared to the control group,
Dp-3-g significantly inhibited platelet aggregation in human and
mouse PRP and purified gel-filtered platelets. Dp-3-g also
markedly reduced thrombus growth in anticoagulated human
and murine blood in perfusion chambers ex vivo, as well as
decreased platelet deposition, destabilized thrombi, and prolonged
the time required for thrombus formation and vessel occlusion in
intravital microscopy and carotid artery thrombosis models in vivo.
We found that Dp-3-g inhibited platelet activation, which broadly
affected platelet a- and d-granule release and cytosol protein
secretion. Dp-3-g decreased active integrin aIIbb3 expression on
the platelet surface, and attenuated the binding of Fg to platelets
Figure 2. Effects of Dp-3-g on human thrombus formation under flow. Ex vivo thrombus formation was monitored on type-I collagen at
600 s
21 or 1800 s
21 using human whole blood with different concentration of Dp-3-g or control buffer. A) Low shear rate of 600 s
21. B) High shear
rate of 1800 s
21. Values are mean 6 SEM, n=5 per group.* P,0.05, ** P,0.01 and *** P,0.001, as compared to control buffer.
doi:10.1371/journal.pone.0037323.g002
Anti-Thrombotic Effects of Delphinidin-3-Glucoside
PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e37323without directly interfering with aIIbb3-Fg interaction. Dp-3-g
also decreased pAMPK, which may in turn decrease aIIbb3
activation through its inside-out signaling. Thus, inhibition of
platelet activation may be the mechanism that explains the anti-
thrombotic effects of Dp-3-g observed in the present study.
The effects of some anthocyanin products on platelet aggrega-
tion have been studied in human whole blood and PRP after
consumption [1,41,42]. However, most studies in vivo have focused
on the effects of food containing anthocyanins, instead of pure
anthocyanin compounds or its bioactive derivatives, leading to
contradictory conclusions regarding their effects on platelet
function. In previous studies, it was demonstrated that querecetin
did not significantly affect platelet aggregation [21,22]. To date,
only one investigation assayed the anti-platelet activity of
physiologically relevant concentrations of four purified anthocya-
nins in vitro and found that anthocyanins inhibited TRAP-induced
platelet aggregation but did not influence platelet reactivity when
stimulated by collagen or ADP [20]. In the present study,
however, we found that the anthocyanin Dp-3-g inhibited platelet
aggregation in both human and mouse PRP stimulated not only
by TRAP, but also by ADP and collagen. In addition, although
there were several studies examining the effect of anthocyanins on
Figure 3. Effects of Dp-3-g on FeCl3-induced thrombosis in vivo. A) Thrombus formation was initiated by topical application of FeCl3 on
mesenteric arterioles in C57BL/6 male mice, which were injected with fluorescently-labeled platelets and different concentration of Dp-3-g or control
buffer. Thrombus formation was compared between groups based on the time to complete vessel occlusion. Values are mean 6 SD, n=6–10 per
group. *** P,0.001, as compared to control buffer. B) C57BL/6 mice were injected with 50 mM Dp-3-g or control buffer. Blood flow in the carotid
artery following FeCl3-induced injury was monitored until complete vessel occlusion was observed. Values are mean 6 SD, n=14 per group. *
P,0.05.
doi:10.1371/journal.pone.0037323.g003
Figure 4. Effects of Dp-3-g on bleeding times in mice. Tail-vein
bleeding times were examined in C57BL/6 mice. Either PBS (control) or
different concentrations of Dp-3-g were administered via the tail vein
40 min before the bleeding time was determined. Values are mean 6
SD, n=8–10 per group. No significant differences in bleeding times
were observed between treated and untreated mice.
doi:10.1371/journal.pone.0037323.g004
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describing the direct effects of these chemicals on platelet function.
Using gel-filtered platelets, in which other molecules in the blood
plasma are removed, we found that the anthocyanin Dp-3-g
directly inhibited platelet aggregation (Figure 1 and S1). Thus, in
addition to possible roles in the inhibition of inflammatory
cytokines [15,43] and elevation of high-density lipoprotein
[17,18], which may indirectly affect platelet activities, Dp-3-g
can inhibit platelet activation independent of other blood
components.
While platelet aggregometry is commonly employed to assess
platelet function, it cannot examine platelet aggregation under
flowing, pathophysiological conditions. The perfusion chamber is
an ex vivo model of thrombosis that has a number of important
advantages over aggregometry, including the ability to assess
thrombus formation on a pathophysiologically relevant substrate
and under flow conditions with different shear stresses. A previous
study used the Gorog Thrombosis Test to examine the anti-
thrombotic effect of whole mulberry fruits under flow conditions
[44]; however, it is difficult to elucidate the effect of anthocyanins
using whole mulberry fruits. Moreover, thrombus formation
cannot be accurately monitored using the Gorog Thrombosis
Test. Therefore, we employed the perfusion chamber model and
monitored the effects of the purified anthocyanin Dp-3-g on
thrombus formation using a confocal intravital microscopy system
[27,31]. We clearly demonstrated that Dp-3-g markedly reduced
thrombus growth at both low and high shear rates using both
human and murine blood at doses as low as 0.5 mM( Figure 2
and S2). These data suggest that Dp-3-g may inhibit thrombosis
at both venous and arterial shear rates.
A role for red wine in supporting cyclic flow reductions (CFRs)
in coronary blood flow has been observed using the Folts model of
mechanically stenosed coronary arteries and intimal damage [45];
however, the role of anthocyanins in mediating thrombus
formation at the site of vascular injury has not been previously
studied. Using intravital microscopy, we observed an inhibitory
effect of the anthocyanin Dp-3-g on thrombus formation in FeCl3-
injured mesenteric arterioles and carotid arteries (Figure 3A and
3B). Therefore, data from our experiments in ex vivo perfusion
chambers and the in vivo thrombosis models are consistent with our
results from in vitro platelet aggregation assays. It is notable that the
inhibition of thrombus growth in these ex vivo and in vivo models
may not only be due to effects on platelet aggregation, but may
also result from the inhibition of platelet adhesion. We found
significantly less adherent platelets in the perfusion chambers
(Figure 2 and S2), and there was a trend toward decreased
platelet deposition at the site of vessel wall injury at the early stages
of thrombus formation in the intravital microscopy model
(Figure 3). This impairment in platelet adhesion may be due to
decreased platelet activation since we did not observe that Dp-3-g
interfered with GPIb complex-VWF interaction induced by
botrocetin and ristocetin (data not shown), which is an important
interaction for platelet adhesion at high shear stress [5]. Thus, Dp-
3-g inhibited platelet activation, adhesion and aggregation, the key
events of thrombosis.
Figure 5. Effects of Dp-3-g on human platelet activation. Human PRP or gel-filtered platelets were incubated with control buffer, 0.5 mM Dp-3-
g, 5 mM Dp-3-g or 50 mM Dp-3-g for 40 min at 37uC. Platelet activation markers were analyzed via flow cytometry after stimulation by ADP, collagen,
TRAP or thrombin. A) P-selectin expression on human PRP. B) P-selectin expression on human gel-filtered platelets. C) CD63 expression on human
gel-filtered platelets. D) CD40L expression on human gel-filtered platelets. Values are mean 6 SEM, n=3 per group. * P,0.05, ** P,0.01 and ***
P,0.001, as compared to control buffer.
doi:10.1371/journal.pone.0037323.g005
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the initiation of atherosclerosis, as well as thrombus formation in
acute manifestations of atherosclerotic diseases [7]. It has been
reported that cocoa flavanol and procyanidin supplementation for
28 days significantly decreased P-selectin expression [46], and that
cocoa consumption reduced ADP- or epinephrine-stimulated
platelet P-selectin and PAC-1 epitope expression and platelet
microparticle formation in vivo [47], and suppressed unstimulated
and stimulated platelet activation in whole blood ex vivo [48]. Our
data showed that Dp-3-g can not only inhibit ADP-, collagen-,
TRAP- and thrombin-stimulated P-selectin, CD63, CD40L, and
PAC-1 epitope expression, but also suppresses Fg binding to
platelets in both human PRP and gel-filtered purified platelets
(Figure 5 and 6). The active conformations of integrin aIIbb3,
detected by the conformation sensitive monoclonal antibody
JON/A and Fg binding, and cell surface P-selectin expression in
ADP- and thrombin-activated mouse platelets, were also inhibited
by Dp-3-g (Figure S3). We found that Dp-3-g did not interfere
with Fg binding to immobilized purified aIIbb3 integrin in vitro
(data not shown). Thus, we propose that the effects of
anthocyanins on platelets may be due to inhibition of platelet
activation, which subsequently decreases platelet a- and d-granule
release and cytoplasmic factor secretion, as well as inhibits integrin
aIIbb3 activation and ligand binding.
The mechanism by which Dp-3-g inhibits platelet activation is
currently unclear. However, several publications suggested that
some polyphenolic compounds can affect platelet signaling
pathways. Cinnamtannin B-1, a naturally occurring trimeric A-
Figure 6. Effects of Dp-3-g on human platelet aIIbb3 activation and fibrinogen binding. Human PRP or gel-filtered platelets were
incubated with control buffer, 0.5 mM Dp-3-g, 5 mM Dp-3-g or 50 mM Dp-3-g for 40 min at 37uC. Platelet activation markers were analyzed via flow
cytometry after stimulation by ADP, collagen, TRAP or thrombin. A) Activated integrin aIIbb3 expression on platelets in human PRP. B) Activated
integrin aIIbb3 expression on human gel-filtered platelets. C) Platelet-bound fibrinogen in human PRP. D) Platelet-bound fibrinogen on human gel-
filtered platelets. Values are mean 6 SEM, n=3 per group. * P,0.05, ** P,0.01 and *** P,0.001, as compared to control buffer.
doi:10.1371/journal.pone.0037323.g006
Figure 7. Effects of Dp-3-g on human and murine platelet
phosphorylation of threonine residues of AMPK. Platelets
activated with collagen in the presence of Dp-3-g were lysed and
proteins were separated by SDS–PAGE and immunoblotted to detect
phospho-threonine residues. A) Western blot analysis of AMPK
phosphorylation in human platelets and the associated percent-change
observed when compared with controls. B) Western blot analysis of
AMPK phosphorylation in murine platelets and the associated percent-
change observed when compared with controls. Values are mean 6 SD,
n=3 per group. * P,0.05 and ** P,0.01, as compared to control buffer.
doi:10.1371/journal.pone.0037323.g007
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inhibition of Ca
2+ mobilization and subsequent aggregation in
platelets [49]. Delphinidin, a dietary anthocyanidin, inhibits
platelet-derived growth factor ligand-receptor (PDGF-PDGFR)
signaling [50]. Genistein affects Ca
2+ mobilization, subsequent
platelet degranulation and aggregation. Both quercetin and
apigenin have been shown to inhibit kinase activation, which
may also be involved in the impairment of platelet responses [51],
while quercetin alone has been shown to inhibit collagen-
stimulated platelet activation through inhibition of multiple
components of the GPVI signaling pathway [52]. Until the
present study, however, there have been no studies to address the
effects of a pure anthocyanin compound on platelet signaling
pathways.
AMPK, a key sensor of cell energy status, has recently been
demonstrated to be involved in platelet signaling. Activated
platelets can induce pAMPK generation, which may induce
phosphorylation of the cytoplasmic tail of integrin aIIbb3 via an
intracellular signalling cascade [40]. This inside-out signaling may
lead to conformational changes in the extracellular domains of
aIIbb3 and affect ligand binding, which is required for clot
retraction and thrombus stability [36,40,53]. Our data clearly
demonstrated that Dp-3-g can down-regulate the phosphorylation
of AMPK in both human and mouse platelets following
stimulation of platelets with the pathophysiological agonist
collagen (Figure 7), which may attenuate aIIbb3 inside-out
signaling and inhibit platelet aggregation and thrombus growth.
Our data, however, cannot exclude the possibility that other
platelet signaling pathways may also be inhibited by Dp-3-g. This
question, including the possible tissue-specific signaling pathways
mediated by anthrocyanins in platelets versus other cells [1,51,53],
merit further investigation.
Anthocyanins are natural pigments responsible for the blue,
purple, red and orange colors of many fruits, vegetables and other
plants. Daily consumption of total anthocyanins has been
estimated to be between 3 and 215 mg/day [54,55]. The
concentration of anthocyanins in plasma ranged from 0.5–
1.0 mM 1.5 hours following consumption [56,57]. Furthermore,
anthocyanins have been reported to show different pharmacolog-
ical properties at high concentrations, including immunomodula-
tory actions, anti-inflammatory actions, low-density lipoprotein
inhibition, and the reduction of CVDs [58–60]. In the present
study, the concentrations of the anthocyanins used are within the
range between the physiological level and the pharmacological
dose (0.5–50 mM) [20]. It is conceivable that the dose to attain the
anti-thrombotic effects may be lower in those who have sub-
optimal hemostatic factors (e.g. conditions of hemophilia or von
Willebrand disease) since we found that Dp-3-g more potently
inhibited platelet aggregation of b3-integrin heterozygous mice
compared to their wild-type littermate controls (data not shown).
Therefore, it is likely that the effects we observed will contribute to
the protective and potential pharmacological effects of anthocya-
nins against thrombosis and CVDs.
Collectively, this study, to the best of our knowledge, is the first
to show the effect of the anthocyanin Dp-3-g on platelet function.
We found that Dp-3-g significantly inhibits human and murine
platelet aggregation, including that with purified platelets, and
attenuates thrombus formation at both arterial and venous shear
stresses. We determined that Dp-3-g can directly inhibit platelet
activation induced by various agonists, which likely explains its
inhibitory roles in platelet aggregation and thrombus formation.
We further demonstrated that Dp-3-g can attenuate platelet
AMPK phosphorylation induced by collagen. Our study suggests
that daily consumption of anthocyanins may play an important
protective role against CVDs, including decreasing platelet-
mediated inflammation and atherosclerosis. The mechanisms of
this inhibitory effect on platelet activation, particularly on platelet
signaling pathways, merit future studies.
Supporting Information
Figure S1 Effects of Dp-3-g on mouse platelet aggrega-
tion. Mouse PRP and gel-filtered platelets were pre-incubated
with control buffer (black), 0.5 mM (blue), 5 mM (green) or 50 mM
(red) for 40 min at 37uC. Aggregation of mouse PRP and gel-
filtered platelets were performed at 37uC with a stir speed of
1000 rpm using an aggregometer. A) Mouse PRP. B) Mouse gel-
filtered platelets. Values are mean 6 SD, n=3 per group.
(TIF)
Figure S2 Effects of Dp-3-g on mouse thrombus forma-
tion under flow. Ex vivo thrombus formation was monitored on
type-I collagen at 600 s
21 or 1800 s
21 using mouse whole blood
with different concentration of Dp-3-g and control buffer. A) Low
shear rate of 600 s
21. B) High shear rate of 1800 s
21. Values are
mean 6 SEM, n=5 per group.* P,0.05, ** P,0.01 and ***
P,0.001, as compared to control buffer.
(TIF)
Figure S3 Effects of Dp-3-g on mouse platelet activation
and fibrinogen binding. Mouse PRP and gel-filtered platelets
were incubated with control buffer, 0.5 mM, 5 mMo r5 0mM for
40 min at 37uC. Platelet activation markers were analyzed via flow
cytometry after stimulation by ADP, collagen, TRAP and
thrombin. A) P-selectin expression on platelets in mouse PRP. B)
P-selectin expression on mouse gel-filtered platelets. C) Activated
integrin aIIbb3 expression on platelets in mouse PRP. D)
Activated integrin aIIbb3 expression on mouse gel-filtered
platelets. E) Platelet-bound fibrinogen in mouse PRP. F) Platelet-
bound fibrinogen on mouse gel-filtered platelets. Values are mean
6 SEM, n=3 per group. *P,0.05, ** P,0.01 and *** P,0.001,
as compared to control buffer.
(TIF)
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